Affitope AD 02
Alternative Names: AD-02; AD-2; Affitope AD02; Alzheimer AD02Latest Information Update: 02 Oct 2021
At a glance
- Originator AFFiRiS
- Class Alzheimer vaccines; Subunit vaccines
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 23 Jun 2014 Discontinued - Phase-II for Alzheimer's disease in Austria, Germany, France, Croatia, Czech Republic and Slovakia (SC)
- 05 Jun 2014 Efficacy and adverse events data from a phase II trial in Alzheimer's disease (early disease) released by AFFiRiS
- 01 Dec 2013 AFFiRiS completes a phase II trial in Alzheimer's disease in Austria, Croatia, Czech Republic, France, Germany, and Slovakia (NCT01117818)